Search

Your search keyword '"Böhmer, Lara H"' showing total 42 results
Start Over Author "Böhmer, Lara H"
42 results on '"Böhmer, Lara H"'

1. Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies

Author

de Groot, Fleur A., Dekker, Tim J.A., Doorduijn, Jeanette K., Böhringer, Stefan, Brink, Mirian, de Groen, Ruben A.L., de Haan, Lorraine M., Woei-A-Jin, F.J. Sherida H., Noordenbos, Troy, Sijs-Szabo, Aniko, Oudshoorn, Mirjam A., Lam, King H., Diepstra, Arjan, te Boome, Liane C.J., Terpstra, Valeska, Bohmer, Lara H., Nicolae, Alina, Posthuma, Eduardus F.M., Koens, Lianne, Durian, Marc F., Stavast, Jeroen, van der Poel, Marjolein W.M., Hamid, Myrurgia Abdul, Stevens, Wendy B.C., van Rooij, Sjo L.M., Oostvogels, Rimke S., Mühlebner, Angelika, Neelis, Karen J., van den Brand, Michiel, Tousseyn, Thomas, Dierickx, Daan, de Weerdt, Okke, Beeker, Aart, Jansen, Patty M., Kersten, Marie José, Zijlstra, Josée M., Chamuleau, Martine E.D., Veelken, Hendrik, Bromberg, Jacoline C.E., Nijland, Marcel, and Vermaat, Joost S.P.

Published
2024
Full Text
View/download PDF

2. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled Trial.

Author

Starreveld, Daniëlle EJ, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus JW, Habers, G Esther A, Bosch, Jos A, Janus, Cécile PM, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik WA, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, and Bleiker, Eveline MA

Subjects
cancer-related fatigue, circadian rhythms, light therapy, randomized controlled trial, sleep, Clinical Research, Depression, Rehabilitation, Rare Diseases, Lymphoma, Cancer, Clinical Trials and Supportive Activities, Behavioral and Social Science, Sleep Research, Hematology, Mental Health, Oncology and Carcinogenesis
Abstract

PurposeTo evaluate the short- and long-term effects of light therapy on fatigue (primary outcome) and sleep quality, depression, anxiety, quality of life, and circadian rhythms (secondary outcomes) in survivors of (non-)Hodgkin lymphoma presenting with chronic cancer-related fatigue.MethodsWe randomly assigned 166 survivors (mean survival 13 years) to a bright white light intervention (BWL) or dim white light comparison (DWL) group. Measurements were completed at baseline (T0), post-intervention (T1), at three (T2), and nine (T3) months follow-up. A mixed-effect modeling approach was used to compare linear and non-linear effects of time between groups.ResultsThere were no significant differences between BWL and DWL in the reduction in fatigue over time. Both BWL and DWL significantly (p < 0.001) improved fatigue levels during the intervention followed by a slight reduction in this effect during follow-up (EST0-T1 = -0.71; EST1-T3 = 0.15). Similar results were found for depression, sleep quality, and some aspects of quality of life. Light therapy had no effect on circadian rhythms.ConclusionsBWL was not superior in reducing fatigue compared to DWL in HL and DLBCL survivors. Remarkably, the total sample showed clinically relevant and persistent improvements on fatigue not commonly seen in longitudinal observational studies in these survivors.

Published
2021

3. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Author

de Groen, Ruben A.L., van Eijk, Ronald, Böhringer, Stefan, van Wezel, Tom, Raghoo, Richard, Ruano, Dina, Jansen, Patty M., Briaire-de Bruijn, Inge, de Groot, Fleur A., Kleiverda, Karin, te Boome, Liane, Terpstra, Valeska, Levenga, Henriette, Nicolae, Alina, Posthuma, Eduardus F.M., Focke-Snieders, Isabelle, Hardi, Lizan, den Hartog, Wietske C.E., Bohmer, Lara H., Hogendoorn, Pancras C.W., van den Berg, Anke, Diepstra, Arjan, Nijland, Marcel, Lugtenburg, Pieternella J., Kersten, Marie José, Pals, Steven T., Veelken, Hendrik, Bovée, Judith V.M.G., Cleven, Arjen H.G., and Vermaat, Joost S.P.

Published
2021
Full Text
View/download PDF

5. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Cancer, Verpleegkundig specialisten & PA's, MS Hematologie, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., te Boome, LCJ, Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., Schaapveld, Michael, Cancer, Verpleegkundig specialisten & PA's, MS Hematologie, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., te Boome, LCJ, Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., and Schaapveld, Michael

Published
2024

6. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., Te Boome, Liane C.J., Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., Schaapveld, Michael, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., Te Boome, Liane C.J., Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., and Schaapveld, Michael

Abstract

PURPOSEFemale Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages.METHODSWe assessed BC risk in a cohort of 1,964 female 5-year HL survivors, treated at age 15-50 years in 20 Dutch hospitals between 1975 and 2008. We calculated standardized incidence ratios, absolute excess risks, and cumulative incidences. Doxorubicin exposure was analyzed using multivariable Cox regression analyses.RESULTSAfter a median follow-up of 21.6 years (IQR, 15.8-27.1 years), 252 women had developed invasive BC or ductal carcinoma in situ. The 30-year cumulative incidence was 20.8% (95% CI, 18.2 to 23.4). Survivors treated with a cumulative doxorubicin dose of >200 mg/m2 had a 1.5-fold increased BC risk (95% CI, 1.08 to 2.1), compared with survivors not treated with doxorubicin. BC risk increased 1.18-fold (95% CI, 1.05 to 1.32) per additional 100 mg/m2 doxorubicin (Ptrend =.004). The risk increase associated with doxorubicin (yes v no) was not modified by age at first treatment (hazard ratio [HR]age <21 years, 1.5 [95% CI, 0.9 to 2.6]; HRage ≥21 years, 1.3 [95% CI, 0.9 to 1.9) or chest RT (HRwithout mantle/axillary field RT, 1.9 [95% CI, 1.06 to 3.3]; HRwith mantle/axillary field RT, 1.2 [95% CI, 0.8 to 1.8]).CONCLUSIONThis study shows that treatment with doxorubicin is associated with increased BC risk in both adolescent and adult HL survivors. Our results have implications for BC surveillance guidelines for HL survivors and treatment strategies for patients with newly diagnosed HL.

Published
2024

7. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Neppelenbroek, Suzanne I.M., primary, Geurts, Yvonne M., additional, Aleman, Berthe M.P., additional, Lugtenburg, Pieternella J., additional, Rademakers, Saskia E., additional, de Weijer, Roel J., additional, Schippers, Maaike G.A., additional, Ta, Bastiaan D.P., additional, Plattel, Wouter J., additional, Zijlstra, Josée M., additional, van der Maazen, Richard W.M., additional, Nijziel, Marten R., additional, Ong, Francisca, additional, Schimmel, Erik C., additional, Posthuma, Eduardus F.M., additional, Kersten, Marie José, additional, Böhmer, Lara H., additional, Muller, Karin, additional, Koene, Harry R., additional, te Boome, Liane C.J., additional, Bilgin, Yavuz M., additional, de Jongh, Eva, additional, Janus, Cécile P.M., additional, van Leeuwen, Flora E., additional, and Schaapveld, Michael, additional

Published
2024
Full Text
View/download PDF

8. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

Author

Chamuleau, Martine E D, primary, Stenner, Frank, additional, Chitu, Dana A, additional, Novak, Urban, additional, Minnema, Monique C, additional, Geerts, Paul, additional, Stevens, Wendy B C, additional, Zenz, Thorsten, additional, van Imhoff, Gustaaf W, additional, Wu, Ka Lung, additional, Demandt, Astrid M P, additional, Kersten, Marie Jose, additional, Terpstra, Wim E, additional, Tick, Lidwine W, additional, Deeren, Dries, additional, Van Den Neste, Eric, additional, Gregor, Michael, additional, Veelken, Hendrik, additional, Böhmer, Lara H, additional, Caspar, Clemens B, additional, Mutsaers, Pim, additional, Refos, Jeannine M, additional, Sewsaran, Robby, additional, Fu, Liping, additional, Seefat, Rianne L, additional, Uyl-de Groot, Carin A, additional, Dirnhofer, Stefan, additional, Van Den Brand, Michiel, additional, de Jong, Daphne, additional, Nijland, Marcel, additional, and Lugtenburg, Pieternella, additional

Published
2023
Full Text
View/download PDF

10. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling

Author

Lawless, Sarah, Iacobelli, Simona, Knelange, Nina Simone, Chevallier, Patrice, Blaise, Didier, Milpied, Noel, Foà, Roberto, Cornelissen, Jan J., Lioure, Bruno, Benjamin, Ruben, Poiré, Xavier, Minnema, Monique C., Collin, Matthew, Lenhoff, Stig, Snowden, John A., Santarone, Stella, Wilson, Keith M.O., Trigo, Fernanda, Dreger, Peter, Böhmer, Lara H., Putter, Hein, Garderet, Laurent, Kröger, Nicolaus, Yaukoub-Agha, Ibrahim, Schönland, Stefan, Morris, Curly, Lawless, Sarah, Iacobelli, Simona, Knelange, Nina Simone, Chevallier, Patrice, Blaise, Didier, Milpied, Noel, Foà, Roberto, Cornelissen, Jan J., Lioure, Bruno, Benjamin, Ruben, Poiré, Xavier, Minnema, Monique C., Collin, Matthew, Lenhoff, Stig, Snowden, John A., Santarone, Stella, Wilson, Keith M.O., Trigo, Fernanda, Dreger, Peter, Böhmer, Lara H., Putter, Hein, Garderet, Laurent, Kröger, Nicolaus, Yaukoub-Agha, Ibrahim, Schönland, Stefan, and Morris, Curly

Abstract

Primary plasma cell leukemia (pPCL) is a rare and challenging malignancy. There are limited data regarding optimum transplant approaches. We therefore undertook a retrospective analysis from 1998-2014 of 751 patients with pPCL undergoing one of four transplant strategies; single autologous transplant (single auto), single allogeneic transplant (allo-first) or a combined tandem approach with an allogeneic transplant following an autologous transplant (auto-allo) or a tandem autologous transplant (auto-auto). To avoid time bias, multiple analytic approaches were employed including Cox models with time-dependent covariates and dynamic prediction by landmarking. Initial comparisons were made between patients undergoing allo-first (n=70) versus auto-first (n=681), regardless of a subsequent second transplant. The allo-first group had a lower relapse rate (45.9%, 95% confidence interval [95% CI]: 33.2-58.6 vs. 68.4%, 64.4-72.4) but higher non-relapse mortality (27%, 95% CI: 15.9-38.1 vs. 7.3%, 5.2-9.4) at 36 months. Patients who underwent allo-first had a remarkably higher risk in the first 100 days for both overall survival and progression-free survival. Patients undergoing auto-allo (n=122) had no increased risk in the short term and a significant benefit in progression-free survival after 100 days compared to those undergoing single auto (hazard ratio [HR]=0.69, 95% CI: 0.52- 0.92; P=0.012). Auto-auto (n=117) was an effective option for patients achieving complete remission prior to their first transplant, whereas in patients who did not achieve complete remission prior to transplantation our modeling predicted that auto-allo was superior. This is the largest retrospective study reporting on transplantation in pPCL to date. We confirm a significant mortality risk within the first 100 days for allo-first and suggest that tandem transplant strategies are superior. Disease status at time of transplant influences outcome. This knowledge may help to guide clinical decisi

Published
2023

11. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Chamuleau, Martine E D, Stenner, Frank, Chitu, Dana A, Novak, Urban, Minnema, Monique C, Geerts, Paul, Stevens, Wendy B C, Zenz, Thorsten, van Imhoff, Gustaaf W, Wu, Ka Lung, Demandt, Astrid M P, Kersten, Marie Jose, Terpstra, Wim E, Tick, Lidwine W, Deeren, Dries, Van Den Neste, Eric, Gregor, Michael, Veelken, Hendrik, Böhmer, Lara H, Caspar, Clemens B, Mutsaers, Pim, Refos, Jeannine M, Sewsaran, Robby, Fu, Liping, Seefat, Rianne L, Uyl-de Groot, Carin A, Dirnhofer, Stefan, Van Den Brand, Michiel, de Jong, Daphne, Nijland, Marcel, Lugtenburg, Pieternella, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Chamuleau, Martine E D, Stenner, Frank, Chitu, Dana A, Novak, Urban, Minnema, Monique C, Geerts, Paul, Stevens, Wendy B C, Zenz, Thorsten, van Imhoff, Gustaaf W, Wu, Ka Lung, Demandt, Astrid M P, Kersten, Marie Jose, Terpstra, Wim E, Tick, Lidwine W, Deeren, Dries, Van Den Neste, Eric, Gregor, Michael, Veelken, Hendrik, Böhmer, Lara H, Caspar, Clemens B, Mutsaers, Pim, Refos, Jeannine M, Sewsaran, Robby, Fu, Liping, Seefat, Rianne L, Uyl-de Groot, Carin A, Dirnhofer, Stefan, Van Den Brand, Michiel, de Jong, Daphne, Nijland, Marcel, and Lugtenburg, Pieternella

Published
2023

12. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Lawless, Sarah, Iacobelli, Simona, Knelange, Nina Simone, Chevallier, Patrice, Blaise, Didier, Milpied, Noel, Foà, Roberto, Cornelissen, Jan J, Lioure, Bruno, Benjamin, Ruben, Poiré, Xavier, Minnema, Monique C, Collin, Matthew, Lenhoff, Stig, Snowden, John A, Santarone, Stella, Wilson, Keith M O, Trigo, Fernanda, Dreger, Peter, Böhmer, Lara H, Putter, Hein, Garderet, Laurent, Kröger, Nicolaus, Yaukoub-Agha, Ibrahim, Schönland, Stefan, Morris, Curly, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Lawless, Sarah, Iacobelli, Simona, Knelange, Nina Simone, Chevallier, Patrice, Blaise, Didier, Milpied, Noel, Foà, Roberto, Cornelissen, Jan J, Lioure, Bruno, Benjamin, Ruben, Poiré, Xavier, Minnema, Monique C, Collin, Matthew, Lenhoff, Stig, Snowden, John A, Santarone, Stella, Wilson, Keith M O, Trigo, Fernanda, Dreger, Peter, Böhmer, Lara H, Putter, Hein, Garderet, Laurent, Kröger, Nicolaus, Yaukoub-Agha, Ibrahim, Schönland, Stefan, and Morris, Curly

Published
2023

13. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Author

Kersten, Marie José, primary, Dreyling, Martin, additional, Linton, Kim M., additional, Chitu, Dana, additional, Tonino, Sanne, additional, Kap, Marcel, additional, Liu, Roberto D, additional, Chamuleau, Martine E.D., additional, Visser, Hein P.J., additional, De Jongh, Eva, additional, Marijt, Erik WAF, additional, Leijs, Maria B.L., additional, Bilgin, Yavuz M., additional, Dürig, Jan, additional, McKay, Pamela, additional, Snijders, Tjeerd J.F., additional, Pettitt, Andrew, additional, Minnema, Monique C., additional, Prange-Krex, Gabriele, additional, Cuijpers, Maria, additional, Böhmer, Lara H., additional, Tick, Lidwine W., additional, Florschütz, Axel, additional, Silbermann, Matthijs, additional, Fijnheer, Rob, additional, Beeker, Aart, additional, Tolboom, Nelleke, additional, Mitea, Cristina, additional, Arens, Anne IJ, additional, Zwezerijnen, Gerben JC, additional, Klapper, Wolfram, additional, Coupland, Sarah E., additional, de Jong, Daphne, additional, Doorduijn, Jeanette K., additional, and Zijlstra, Josée M., additional

Published
2022
Full Text
View/download PDF

14. Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Author

De Groen, Ruben A.L., primary, De Groot, Fleur A, additional, De Haan, Lorraine M., additional, van Wezel, Tom, additional, Noordenbos, Troy, additional, Boehringer, Stefan, additional, Van Eijk, Ronald, additional, Raghoo, Richard, additional, Ruano, Dina, additional, Sijs-Szabo, Aniko, additional, te Boome, Liane, additional, Terpstra, Valeska, additional, Levenga, Henriette, additional, Nicolae, Aline, additional, Posthuma, Ward, additional, Focke-Snieders, Isabelle, additional, Hardi, Lizan, additional, den Hartog, Wietske, additional, Böhmer, Lara H., additional, Van Den Berg, Anke, additional, Mutseaers, Pim, additional, Van Der Poel, Marjolein W.M., additional, Abdul Hamid, Myrurgia, additional, Woei-a-Jin, F.J. Sherida H., additional, Janssens, Ann, additional, Tousseyn, Thomas, additional, Bovée, Judith, additional, Veelken, Hendrik, additional, Pals, Steven T, additional, Diepstra, Arjan, additional, Nijland, Marcel, additional, Kersten, Marie José, additional, Jansen, Patty M., additional, Cleven, Arjen, additional, and Vermaat, Joost S.P., additional

Published
2022
Full Text
View/download PDF

15. Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Author

de Jonge, A.Vera, primary, Duetz, Carolien, additional, Bruins, Wassilis S.C., additional, van Werkhoven, Erik D., additional, Nijland, Marcel, additional, Van Der Poel, Marjolein W.M., additional, de Heer, Koen, additional, Klerk, Clara P.W., additional, Sandberg, Yorick, additional, Fijnheer, Rob, additional, Mutseaers, Pim, additional, Issa, Djamila E., additional, Böhmer, Lara H., additional, Van Kampen, Roel J.W., additional, Visser, Otto J., additional, de Jong, Daphne, additional, Zijlstra, Josée M., additional, Mutis, Tuna, additional, and Chamuleau, Martine E.D., additional

Published
2022
Full Text
View/download PDF

16. Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

Author

De Groot, Fleur A, primary, Doorduijn, Jeanette K., additional, Brink, Mirian, additional, De Groen, Ruben A.L., additional, De Haan, Lorraine M., additional, Noordenbos, Troy, additional, Sijs-Szabo, Aniko, additional, Lam, King Hong, additional, Diepstra, Arjan, additional, te Boome, Liane, additional, Terpstra, Valeska, additional, Böhmer, Lara H., additional, Zijlstra, Josée M., additional, Koens, Lianne, additional, Durian, Marc, additional, Oudshoorn, Mirjam A., additional, Veelken, Hendrik, additional, Van Der Poel, Marjolein W.M., additional, Abdul Hamid, Myrurgia, additional, Stevens, Wendy B.C., additional, van Rooij, J L.M, additional, Oostvogels, Rimke, additional, Neelis, Karen J., additional, van den Brand, Michiel, additional, Woei-a-Jin, F.J. Sherida H., additional, Tousseyn, Thomas, additional, Dierickx, Daan, additional, Jansen, Patty M., additional, Kersten, Marie Jose, additional, Bromberg, Jacoline, additional, Nijland, Marcel, additional, and Vermaat, Joost S.P., additional

Published
2022
Full Text
View/download PDF

17. T064: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

Author

Neppelenbroek, Suzanne I.M., primary, Geurts, Yvonne M.G., additional, Aleman, Berthe M. P., additional, Janus, Cécile P.M., additional, Lugtenburg, Pieternella J., additional, Rademaker, Saskia E., additional, De Weijer, Roel J., additional, Schippers, Maaike G.A., additional, Ta, Bastiaan D.P., additional, Plattel, Wouter J., additional, Zijlstra, Josée. M., additional, Van Der Maazen, Richard W.M., additional, Nijziel, Marten R., additional, Ong, Francisca, additional, Schimmel, Erik C., additional, Posthuma, Eduardus F.M., additional, Kersten, Marie José, additional, Böhmer, Lara H., additional, Muller, Karin, additional, Koene, Harry R., additional, Te Boome, Liane C.J., additional, Bilgin, Yavuz M., additional, De Jongh, Eva, additional, Van Leeuwen, Flora E., additional, and Schaapveld, Michael, additional

Published
2022
Full Text
View/download PDF

18. Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study

Author

Brink, Mirian, primary, Meeuwes, Frederik O., additional, van der Poel, Marjolein W. M., additional, Kersten, Marie José, additional, Wondergem, Mariëlle, additional, Mutsaers, Pim G. N. J., additional, Böhmer, Lara H., additional, Woei-A-Jin, F. J. Sherida H., additional, Visser, Otto, additional, Oostvogels, Rimke, additional, Jansen, Patty M., additional, Plattel, Wouter, additional, Huls, Gerwin A., additional, Vermaat, Joost S. P., additional, and Nijland, Marcel, additional

Published
2022
Full Text
View/download PDF

19. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling

Author

Lawless, Sarah, primary, Iacobelli, Simona, additional, Knelange, Nina Simone, additional, Chevallier, Patrice, additional, Blaise, Didier, additional, Milpied, Noel, additional, Foà, Roberto, additional, Cornelissen, Jan J., additional, Lioure, Bruno, additional, Benjamin, Ruben, additional, Poiré, Xavier, additional, Minnema, Monique C., additional, Collin, Matthew, additional, Lenhoff, Stig, additional, Snowden, John A., additional, Santarone, Stella, additional, Wilson, Keith M. O., additional, Trigo, Fernanda, additional, Dreger, Peter, additional, Böhmer, Lara H., additional, Putter, Hein, additional, Garderet, Laurent, additional, Kröger, Nicolaus, additional, Yaukoub-Agha, Ibrahim, additional, Schönland, Stefan, additional, and Morris, Curly, additional

Published
2022
Full Text
View/download PDF

20. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL:a population-based cohort study

Author

Brink, Mirian, Meeuwes, Frederik O., van der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara H., Woei-A-Jin, F. J.Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Plattel, Wouter, Huls, Gerwin A., Vermaat, Joost S.P., Nijland, Marcel, Brink, Mirian, Meeuwes, Frederik O., van der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara H., Woei-A-Jin, F. J.Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Plattel, Wouter, Huls, Gerwin A., Vermaat, Joost S.P., and Nijland, Marcel

Abstract

Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although the addition of etoposide (CHOEP) and consolidation with autologous stem cell transplantation (ASCT) are preferred in some countries, randomized trials are lacking. This nationwide population-based study assessed the impact of etoposide and ASCT on overall survival (OS) among patients aged 18 to 64 years with stage II to IV anaplastic large-cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), or PTCL not otherwise specified (NOS) diagnosed between 1989 and 2018 using the Netherlands Cancer Registry. Patients were categorized into 2 calendar periods, representing pre- and post-eras of etoposide and ASCT, respectively. A total of 1427 patients were identified (ALCL, 35%; AITL, 21%; and PTCL NOS, 44%). OS increased from 39% in the period from 1989 to 2009 to 49% in the period of 2009 to 2018 (P < .01). Five-year OS was superior for patients treated with CHOEP vs CHOP (64% and 44%, respectively; P < .01). When adjusted for subtype, International Prognostic Index score, and ASCT, the risk of mortality was similar between the 2 groups, except for patients with ALK+ ALCL, for whom the risk of mortality was 6.3 times higher when treated with CHOP vs CHOEP. Patients undergoing consolidation with ASCT had superior 5-year OS of 81% compared with 39% for patients not undergoing ASCT (P < .01), regardless of whether complete remission was achieved. In patients aged <65 years with advanced-stage ALK− ALCL, AITL, or PTCL, the use of ASCT consolidation, but not the addition of etoposide, was associated with improved OS.

Published
2022

21. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstrom's Macroglobulinemia:Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study

Author

Kersten, Marie José, Amaador, Karima, Minnema, Monique C., Vos, Josephine M.I., Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E.D., Deeren, Dries, Tick, Lidwine W., Doorduijn, Jeanette K., Offner, Fritz, Böhmer, Lara H., Liu, Roberto D., Pals, Steven T., Dimopoulos, Meletios A., Kersten, Marie José, Amaador, Karima, Minnema, Monique C., Vos, Josephine M.I., Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E.D., Deeren, Dries, Tick, Lidwine W., Doorduijn, Jeanette K., Offner, Fritz, Böhmer, Lara H., Liu, Roberto D., Pals, Steven T., and Dimopoulos, Meletios A.

Abstract

PURPOSE: Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor ixazomib combined with rituximab, in patients with relapsed WM. METHODS: resultsWe conducted a multicenter phase I/II trial with ixazomib, rituximab, and dexamethasone (IRD). Induction consisted of eight cycles IRD wherein rituximab was started in cycle 3, followed by rituximab maintenance. Phase I showed feasibility of 4 mg ixazomib. Primary end point for phase II was overall response rate (ORR [≥ minimal response]) after induction. RESULTS: A total of 59 patients were enrolled (median age, 69 years; range, 46-91 years). Median number of prior treatments was 2 (range, 1-7); 70% had an intermediate or high WM-IPSS (International Prognostic Scoring System for WM) score. After eight cycles, ORR was 71% (42 out of 59) (14% very good partial response [PR], 37% PR, and 20% minor response). Depth of response improved until month 12 (best ORR methods85% [50 out of 59]: 15% very good PR, 46% PR, and 24% minor response). Median duration of response was 36 months. The average hematocrit level increased significantly (0.33-0.38 L/L) after induction (P < .001). After two cycles of ixazomib and dexamethasone, immunoglobulin M levels decreased significantly (median 3,700-2,700 mg/dL, P < .0001). Median time to first response was 4 months. Median progression-free survival and overall survival were not reached. After median follow-up of 24 months (range, 7.4-54.3 months), progression-free survival and overall survival were 56% and 88%, respectively. Toxicity included mostly grade 2 or 3 cytopenias, grade 1 or 2 neurotoxicity, and grade 2 or 3 infections. No infusion-related reactions or immunoglobulin M flare occurred with use of subcutaneous rituximab. Quality of life imp

Published
2022

22. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Brink, Mirian, Meeuwes, Frederik O., van der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara H., Woei-A-Jin, F. J.Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Plattel, Wouter, Huls, Gerwin A., Vermaat, Joost S.P., Nijland, Marcel, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Brink, Mirian, Meeuwes, Frederik O., van der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara H., Woei-A-Jin, F. J.Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Plattel, Wouter, Huls, Gerwin A., Vermaat, Joost S.P., and Nijland, Marcel

Published
2022

23. R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Author

MS Hematologie, Cancer, Al-Sarayfi, Diana, Meeuwes, Frederik O., Durmaz, Müjde, Issa, Djamila E., Brouwer, Rolf E., Beeker, Aart, van Rhenen, Anna, Mutsaers, Pim G.N.J., Böhmer, Lara H., van der Poel, Marjolein W.M., te Boome, Liane, van Meerten, Tom, Chamuleau, Martine E.D., Zijlstra, Josée M., Brink, Mirian, Nijland, Marcel, MS Hematologie, Cancer, Al-Sarayfi, Diana, Meeuwes, Frederik O., Durmaz, Müjde, Issa, Djamila E., Brouwer, Rolf E., Beeker, Aart, van Rhenen, Anna, Mutsaers, Pim G.N.J., Böhmer, Lara H., van der Poel, Marjolein W.M., te Boome, Liane, van Meerten, Tom, Chamuleau, Martine E.D., Zijlstra, Josée M., Brink, Mirian, and Nijland, Marcel

Published
2022

24. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study

Author

Onderzoek NEU, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Kersten, Marie José, Amaador, Karima, Minnema, Monique C, Vos, Josephine M I, Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E D, Deeren, Dries, Tick, Lidwine W, Doorduijn, Jeanette K, Offner, Fritz, Böhmer, Lara H, Liu, Roberto D, Pals, Steven T, Dimopoulos, Meletios A, Onderzoek NEU, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Kersten, Marie José, Amaador, Karima, Minnema, Monique C, Vos, Josephine M I, Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E D, Deeren, Dries, Tick, Lidwine W, Doorduijn, Jeanette K, Offner, Fritz, Böhmer, Lara H, Liu, Roberto D, Pals, Steven T, and Dimopoulos, Meletios A

Published
2022

25. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study

Author

Kersten, Marie José, primary, Amaador, Karima, additional, Minnema, Monique C., additional, Vos, Josephine M. I., additional, Nasserinejad, Kazem, additional, Kap, Marcel, additional, Kastritis, Efstathios, additional, Gavriatopoulou, Maria, additional, Kraan, Willem, additional, Chamuleau, Martine E. D., additional, Deeren, Dries, additional, Tick, Lidwine W., additional, Doorduijn, Jeanette K., additional, Offner, Fritz, additional, Böhmer, Lara H., additional, Liu, Roberto D., additional, Pals, Steven T., additional, and Dimopoulos, Meletios A., additional

Published
2022
Full Text
View/download PDF

26. First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study

Author

Meeuwes, Frederik O., primary, Brink, Mirian, additional, Van Der Poel, Marjolein W.M., additional, Kersten, Marie José, additional, Wondergem, Mariëlle, additional, Mutsaers, Pim G.N.J., additional, Böhmer, Lara H., additional, Woei-a-Jin, F.J. Sherida H., additional, Visser, Otto J., additional, Oostvogels, Rimke, additional, Jansen, Patty M., additional, Neelis, Karen J., additional, Crijns, Anne P.G., additional, Daniëls, Laurien A., additional, Vermaat, Joost S.P., additional, Huls, Gerwin A., additional, and Nijland, Marcel, additional

Published
2021
Full Text
View/download PDF

27. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled Trial

Author

Starreveld, Daniëlle E J, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus J W, Habers, G Esther A, Bosch, Jos A, Janus, Cécile P M, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik W A, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, Bleiker, Eveline M A, Starreveld, Daniëlle E J, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus J W, Habers, G Esther A, Bosch, Jos A, Janus, Cécile P M, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik W A, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, and Bleiker, Eveline M A

Abstract

PURPOSE: To evaluate the short- and long-term effects of light therapy on fatigue (primary outcome) and sleep quality, depression, anxiety, quality of life, and circadian rhythms (secondary outcomes) in survivors of (non-)Hodgkin lymphoma presenting with chronic cancer-related fatigue.METHODS: We randomly assigned 166 survivors (mean survival 13 years) to a bright white light intervention (BWL) or dim white light comparison (DWL) group. Measurements were completed at baseline (T0), post-intervention (T1), at three (T2), and nine (T3) months follow-up. A mixed-effect modeling approach was used to compare linear and non-linear effects of time between groups.RESULTS: There were no significant differences between BWL and DWL in the reduction in fatigue over time. Both BWL and DWL significantly (p < 0.001) improved fatigue levels during the intervention followed by a slight reduction in this effect during follow-up (EST0-T1 = -0.71; EST1-T3 = 0.15). Similar results were found for depression, sleep quality, and some aspects of quality of life. Light therapy had no effect on circadian rhythms.CONCLUSIONS: BWL was not superior in reducing fatigue compared to DWL in HL and DLBCL survivors. Remarkably, the total sample showed clinically relevant and persistent improvements on fatigue not commonly seen in longitudinal observational studies in these survivors.

Published
2021

28. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors:Results of a Randomized Controlled Trial

Author

Starreveld, Daniëlle E J, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus J W, Habers, G Esther A, Bosch, Jos A, Janus, Cécile P M, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik W A, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, Bleiker, Eveline M A, Starreveld, Daniëlle E J, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus J W, Habers, G Esther A, Bosch, Jos A, Janus, Cécile P M, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik W A, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, and Bleiker, Eveline M A

Abstract

PURPOSE: To evaluate the short- and long-term effects of light therapy on fatigue (primary outcome) and sleep quality, depression, anxiety, quality of life, and circadian rhythms (secondary outcomes) in survivors of (non-)Hodgkin lymphoma presenting with chronic cancer-related fatigue.METHODS: We randomly assigned 166 survivors (mean survival 13 years) to a bright white light intervention (BWL) or dim white light comparison (DWL) group. Measurements were completed at baseline (T0), post-intervention (T1), at three (T2), and nine (T3) months follow-up. A mixed-effect modeling approach was used to compare linear and non-linear effects of time between groups.RESULTS: There were no significant differences between BWL and DWL in the reduction in fatigue over time. Both BWL and DWL significantly (p < 0.001) improved fatigue levels during the intervention followed by a slight reduction in this effect during follow-up (EST0-T1 = -0.71; EST1-T3 = 0.15). Similar results were found for depression, sleep quality, and some aspects of quality of life. Light therapy had no effect on circadian rhythms.CONCLUSIONS: BWL was not superior in reducing fatigue compared to DWL in HL and DLBCL survivors. Remarkably, the total sample showed clinically relevant and persistent improvements on fatigue not commonly seen in longitudinal observational studies in these survivors.

Published
2021

29. Treatment-specific risk of second malignancies in five-year survivors of diffuse large B-cell lymphoma.

Author

Geurts, Yvonne M., primary, Neppelenbroek, Suzanne I.M., additional, So-Osman, Cynthia, additional, Vermaat, Joost S.P., additional, van Spronsen, Dick Johan, additional, Plattel, Wouter J., additional, de Weijer, Roel J., additional, Verschueren, Karijn M.S., additional, Zijlstra, Josée M., additional, Koene, Harry R., additional, Nijziel, Marten R., additional, Schimmel, Erik C., additional, Böhmer, Lara H., additional, Ong, Francisca, additional, Visser, Hein, additional, van Kampen, Daphne, additional, Kersten, Marie José, additional, Aleman, Berthe M.P., additional, Van Leeuwen, Flora, additional, and Schaapveld, Michael, additional

Published
2021
Full Text
View/download PDF

30. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

Author

Lugtenburg, Pieternella Johanna, primary, de Nully Brown, Peter, additional, van der Holt, Bronno, additional, D’Amore, Francesco A., additional, Koene, Harry R., additional, de Jongh, Eva, additional, Fijnheer, Rob, additional, van Esser, Joost W., additional, Böhmer, Lara H., additional, Pruijt, Johannes F., additional, Verhoef, Gregor E., additional, Hoogendoorn, Mels, additional, Bilgin, Memis Y., additional, Nijland, Marcel, additional, van der Burg-de Graauw, Nicole C., additional, Oosterveld, Margreet, additional, Jie, Kon-Siong G., additional, Larsen, Thomas Stauffer, additional, van der Poel, Marjolein W., additional, Leijs, Maria B., additional, Silbermann, Matthijs H., additional, van Marwijk Kooy, Marinus, additional, Beeker, Aart, additional, Kersten, Marie J., additional, Doorduijn, Jeanette K., additional, Tick, Lidwine W., additional, Brouwer, Rolf E., additional, Lam, King H., additional, Burggraaff, Coreline N., additional, de Keizer, Bart, additional, Arens, Anne I., additional, de Jong, Daphne, additional, Hoekstra, Otto S., additional, and Zijlstra-Baalbergen, Josée M., additional

Published
2020
Full Text
View/download PDF

31. Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

Author

Doorduijn, Jeanette K., primary, Zijlstra, Josee M., additional, Lugtenburg, Pieternella J., additional, Kersten, Marie Josee, additional, Böhmer, Lara H., additional, Minnema, Monique C., additional, MacKenzie, Marius A., additional, van Marwijk Kooij, Rien, additional, Jongh, Eva, additional, Snijders, Tjeerd J.F., additional, Weerdt, Okke, additional, Gelder, Michel, additional, Hoogendoorn, Mels, additional, Leys, Rineke B.L., additional, Kibbelaar, Robby E., additional, Jong, Daphne, additional, Chitu, Dana A., additional, Van’t Veer, Mars B., additional, and Kluin‐Nelemans, Hanneke C., additional

Published
2020
Full Text
View/download PDF

32. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study

Author

Brink, Mirian, Meeuwes, Frederik O., van der Poel, Marjolein W. M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G. N. J., Böhmer, Lara H., Woei-A-Jin, F. J. Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Plattel, Wouter, Huls, Gerwin A., Vermaat, Joost S. P., and Nijland, Marcel

Abstract

Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although the addition of etoposide (CHOEP) and consolidation with autologous stem cell transplantation (ASCT) are preferred in some countries, randomized trials are lacking. This nationwide population-based study assessed the impact of etoposide and ASCT on overall survival (OS) among patients aged 18 to 64 years with stage II to IV anaplastic large-cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), or PTCL not otherwise specified (NOS) diagnosed between 1989 and 2018 using the Netherlands Cancer Registry. Patients were categorized into 2 calendar periods, representing pre- and post-eras of etoposide and ASCT, respectively. A total of 1427 patients were identified (ALCL, 35%; AITL, 21%; and PTCL NOS, 44%). OS increased from 39% in the period from 1989 to 2009 to 49% in the period of 2009 to 2018 (P < .01). Five-year OS was superior for patients treated with CHOEP vs CHOP (64% and 44%, respectively; P < .01). When adjusted for subtype, International Prognostic Index score, and ASCT, the risk of mortality was similar between the 2 groups, except for patients with ALK+ ALCL, for whom the risk of mortality was 6.3 times higher when treated with CHOP vs CHOEP. Patients undergoing consolidation with ASCT had superior 5-year OS of 81% compared with 39% for patients not undergoing ASCT (P < .01), regardless of whether complete remission was achieved. In patients aged <65 years with advanced-stage ALK− ALCL, AITL, or PTCL, the use of ASCT consolidation, but not the addition of etoposide, was associated with improved OS.

Published
2022
Full Text
View/download PDF

33. Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study

Author

Lugtenburg, Pieternella J, Zijlstra, Josee M, Doorduijn, Jeanette K, Böhmer, Lara H, Hoogendoorn, Mels, Berenschot, Henriette W, Beeker, Aart, van der Burg-de Graauw, Nicole C, Schouten, Harry C, Bilgin, Yavuz M, Kersten, Marie-Jose, Koene, Harry R, Herbers, Alexandra H E, de Jong, Daphne, Hijmering, Nathalie, Lam, King H, Chiţu, Dana, Brouwer, Rolf E, van Imhoff, Gustaaf W, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Hematology, and Pathology

Subjects
relapse, PLUS RITUXIMAB, IBRITUMOMAB TIUXETAN, diffuse large B-cell lymphoma, MULTICENTER, B-CELL LYMPHOMA, PECC, CHEMOTHERAPY, OPEN-LABEL, TRIAL, Y-90-ibritumomab tiuxetan, COMBINATION, consolidation, ELDERLY-PATIENTS, CHOP
Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with Y-90-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade >= 3 adverse events from start of Y-90-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to Y-90-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after Y-90-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of Y-90-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33-68%) and 62% (95% CI, 42-77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17-39%) and 49% (95% CI, 36-61%), respectively. Toxicities of R-PECC and Y-90-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with Y-90-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Published
2019

34. Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Author

Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Böhmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg-de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie-Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chiţu, Dana, Brouwer, Rolf E., van Imhoff, Gustaaf W., Hematology, CCA - Cancer Treatment and quality of life, Pathology, AGEM - Re-generation and cancer of the digestive system, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, CCA - Cancer Treatment and Quality of Life, and Clinical Haematology

Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with 90Y-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade ≥3 adverse events from start of 90Y-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to 90Y-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after 90Y-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of 90Y-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33–68%) and 62% (95% CI, 42–77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17–39%) and 49% (95% CI, 36–61%), respectively. Toxicities of R-PECC and 90Y-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with 90Y-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Published
2019
Full Text
View/download PDF

35. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Doorduijn, Jeanette K, Zijlstra, Josee M, Lugtenburg, Pieternella J, Kersten, Marie Josee, Böhmer, Lara H, Minnema, Monique C, MacKenzie, Marius A, van Marwijk Kooij, Rien, de Jongh, Eva, Snijders, Tjeerd J F, de Weerdt, Okke, van Gelder, Michel, Hoogendoorn, Mels, Leys, Rineke B L, Kibbelaar, Robby E, de Jong, Daphne, Chitu, Dana A, Van't Veer, Mars B, Kluin-Nelemans, Hanneke C, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Doorduijn, Jeanette K, Zijlstra, Josee M, Lugtenburg, Pieternella J, Kersten, Marie Josee, Böhmer, Lara H, Minnema, Monique C, MacKenzie, Marius A, van Marwijk Kooij, Rien, de Jongh, Eva, Snijders, Tjeerd J F, de Weerdt, Okke, van Gelder, Michel, Hoogendoorn, Mels, Leys, Rineke B L, Kibbelaar, Robby E, de Jong, Daphne, Chitu, Dana A, Van't Veer, Mars B, and Kluin-Nelemans, Hanneke C

Published
2020

36. Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.

Author

Lugtenburg, Elly J., primary, Brown, Peter, additional, van der Holt, Bronno, additional, D'Amore, Francesco, additional, Koene, Harry R, additional, de Jongh, Eva, additional, Fijnheer, Rob, additional, Loosveld, Olaf, additional, Böhmer, Lara H, additional, Pruijt, Hans, additional, Verhoef, Gregor, additional, Hoogendoorn, Mels, additional, Bilgin, Yavuz, additional, Nijland, Marcel, additional, Lam, King H, additional, de Keizer, Bart, additional, de Jong, Daphne, additional, and Zijlstra, Josee M, additional

Published
2019
Full Text
View/download PDF

37. Rituximab‐PECC induction followed by 90Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Author

Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Böhmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg‐de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie‐Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chiţu, Dana, Brouwer, Rolf E., and van Imhoff, Gustaaf W.

Subjects
STEM cell transplantation
Abstract

Summary: Patients with relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R‐PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio‐immunotherapy consolidation with 90Y‐ibritumomab tiuxetan in responsive patients. Primary endpoints were failure‐free survival (FFS) and incidence of grade ≥3 adverse events from start of 90Y‐ibritumomab tiuxetan. The overall response rate after R‐PECC was 50%. Twenty‐nine of 31 responsive patients proceeded to 90Y‐ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after 90Y‐ibritumomab tiuxetan. One‐year FFS and overall survival (OS) from start of 90Y‐ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33–68%) and 62% (95% CI, 42–77%), respectively. One‐year FFS and OS from start of R‐PECC was 28% (95% CI, 17–39%) and 49% (95% CI, 36–61%), respectively. Toxicities of R‐PECC and 90Y‐ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R‐PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with 90Y‐ibritumomab tiuxetan resulted in long‐term response durations in approximately one third of the patients that received it. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

38. Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Author

Kersten, Marie José, Minnema, Monique C., Vos, Josephine M., Nasserinejad, Kazem, Kap, Marcel, Kastritis, Eftathios, Gavriatopoulou, Maria, Chamuleau, Martine E.D., Deeren, Dries, Tick, Lidwine Winnifred, Doorduijn, Jeanette K., Offner, Fritz, Bohmer, Lara H, Amaador, Karima, Liu, Roberto D, Pals, Steven T, and Dimopoulos, Meletios A.

Published
2019
Full Text
View/download PDF

39. Rituximab-Pecc Induction Followed By 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Author

Lugtenburg, Pieternella J, primary, Zijlstra, Josée M, additional, Doorduijn, Jeanette K, additional, Böhmer, Lara H, additional, van Marwijk Kooy, Marinus, additional, Hoogendoorn, Mels, additional, Berenschot, Henriette W, additional, Beeker, Aart, additional, Valster, Fransje, additional, Schouten, Harry C., additional, Luten, Marleen, additional, Hofwegen, Henk, additional, Chitu, Dana A, additional, Brouwer, Rolf E, additional, and van Imhoff, Gustaaf W, additional

Published
2015
Full Text
View/download PDF

40. DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Author

de Jonge, A.Vera, Kersten, Marie José, van Werkhoven, Erik, van der Poel, Marjolein, de Heer, Koen, Klerk, Clara, Sandberg, Yorick, Van Rijn, Rozemarijn S, Fijnheer, Rob, Mutsaers, Pim, Vergote, Vibeke, Issa, Djamila, Beeker, Aart, Bilgin, Yavuz M., Böhmer, Lara H., Nieuwenhuizen, Laurens, Stevens, Wendy, van Kampen, Roel JW, Mous, Rogier, Durian, Marc, Snijders, Tjeerd, Vermaat, Joost S.P, Visser, Otto, Zijlstra, Josée M., Hofwegen, Henk, Zanders, Helma G.J.M., Fu, Liping P., De Jong, Daphne, Nijland, Marcel, and Chamuleau, Martine E.D.

Abstract

Introduction

Published
2023
Full Text
View/download PDF

41. Rituximab-PECC Induction Followed by 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Author

Lugtenburg, Pieternella J, primary, Zijlstra, Josée M, additional, Doorduijn, Jeanette K, additional, Böhmer, Lara H, additional, van Marwijk Kooy, Marinus, additional, Hoogendoorn, Mels, additional, Berenschot, Henriette W, additional, Beeker, Aart, additional, Valster, Fransje A, additional, Schouten, Harry C, additional, Luten, Marleen, additional, Chitu, Dana A, additional, Brouwer, Rolf E, additional, and van Imhoff, Gustaaf W, additional

Published
2012
Full Text
View/download PDF

42. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.

Author

Lawless S, Iacobelli S, Knelange NS, Chevallier P, Blaise D, Milpied N, Foà R, Cornelissen JJ, Lioure B, Benjamin R, Poiré X, Minnema MC, Collin M, Lenhoff S, Snowden JA, Santarone S, Wilson KMO, Trigo F, Dreger P, Böhmer LH, Putter H, Garderet L, Kröger N, Yaukoub-Agha I, Schönland S, and Morris C

Subjects
Humans, Retrospective Studies, Transplantation, Homologous, Disease-Free Survival, Transplantation, Autologous, Recurrence, Leukemia, Plasma Cell diagnosis, Leukemia, Plasma Cell therapy, Hematopoietic Stem Cell Transplantation adverse effects
Abstract

Primary plasma cell leukemia (pPCL) is a rare and challenging malignancy. There are limited data regarding optimum transplant approaches. We therefore undertook a retrospective analysis from 1998-2014 of 751 patients with pPCL undergoing one of four transplant strategies; single autologous transplant (single auto), single allogeneic transplant (allo-first) or a combined tandem approach with an allogeneic transplant following an autologous transplant (auto-allo) or a tandem autologous transplant (auto-auto). To avoid time bias, multiple analytic approaches were employed including Cox models with time-dependent covariates and dynamic prediction by landmarking. Initial comparisons were made between patients undergoing allo-first (n=70) versus auto-first (n=681), regardless of a subsequent second transplant. The allo-first group had a lower relapse rate (45.9%, 95% confidence interval [95% CI]: 33.2-58.6 vs. 68.4%, 64.4-72.4) but higher non-relapse mortality (27%, 95% CI: 15.9-38.1 vs. 7.3%, 5.2-9.4) at 36 months. Patients who underwent allo-first had a remarkably higher risk in the first 100 days for both overall survival and progression-free survival. Patients undergoing auto-allo (n=122) had no increased risk in the short term and a significant benefit in progression-free survival after 100 days compared to those undergoing single auto (hazard ratio [HR]=0.69, 95% CI: 0.52- 0.92; P=0.012). Auto-auto (n=117) was an effective option for patients achieving complete remission prior to their first transplant, whereas in patients who did not achieve complete remission prior to transplantation our modeling predicted that auto-allo was superior. This is the largest retrospective study reporting on transplantation in pPCL to date. We confirm a significant mortality risk within the first 100 days for allo-first and suggest that tandem transplant strategies are superior. Disease status at time of transplant influences outcome. This knowledge may help to guide clinical decisions on transplant strategy.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results